The inability of human immunodeficiency virus type 1(HIV-1) to replicate in rhesus macaque cells is in part due to the failure of HIV-1 Vif to counteract the restriction factor APOBEC3G. However, in this study we demonstrate that several rhesus macaque APOBEC3 (rhAPOBEC3) proteins are capable of inhibiting HIV-1 infectivity. There was considerable variation in the ability of a panel of Vif proteins to induce degradation of rhAPOBEC3 proteins, and mutations within HIV-1 Vif that render it capable of degrading rhAPOBEC3G did not confer activity against other antiviral rhAPOBEC3 proteins. These findings suggest that multiple APOBEC3 proteins can contribute to primate lentivirus species tropism.
Human immunodeficiency virus type 1 (HIV-1) is unable to replicate in most nonhuman primate species, including rhesus macaques. This is at least in part due to blocks in the viral replication cycle that have been identified in macaque-derived cells in vitro. Specifically, the rhesus macaque restriction factors TRIM5␣ and APOBEC3G are major barriers to HIV-1, but not simian immunodeficiency virus strain MAC239 (SIV MAC ), replication in primary rhesus macaque cells (2, 12, 13, 18, 27, 30) . Engineering HIV-1 to avoid and counteract these factors by replacing HIV-1 capsid and Vif proteins with their SIV MAC counterparts results in a virus that can replicate in primary rhesus macaque cells almost as efficiently as SIV MAC (12, 13) .
Mutant HIV-1 Vif proteins that are capable of counteracting rhesus macaque APOBEC3G (rhAPOBEC3G) have recently been described (26) . Specifically, changing amino acids 14 to 19 (from DRMR to SEMQ) resulted in an HIV-1 Vif protein that is capable of counteracting rhAPOBEC3G-mediated restriction. Therefore, we determined whether overcoming rhAPOBEC3G would be sufficient for HIV-1 to replicate in rhesus macaque T cells. The SEMQ substitution was introduced into a chimeric HIV-1 provirus encoding the SIV MAC capsid protein (Fig. 1A) (12) . Since the Vif open reading frame overlaps with that of integrase, the C-terminal five amino acids of HIV-1 integrase were altered from RQDAD to KRDAD. This change did not have a significant effect on the ability of the virus to replicate in human CEMx174 cells, and its replication was only marginally slower than that of viruses expressing SIV MAC capsid and wild-type HIV-1 or SIV MAC Vif proteins (Fig. 1B) . However, only the virus expressing SIV MAC Vif was able to replicate efficiently in rhesus macaque 221 T cells (Fig. 1B) . Since HIV(SEMQ) Vif can counteract rhAPOBEC3G, this finding suggests that rhAPOBEC3G is not the only Vif-targeted restriction factor active in rhesus macaque T cells.
The APOBEC3 family expanded during mammalian evolution, and many of its members have been under strong positive selection pressure in primates (6, 23) , presumably as a consequence of past retroviral epidemics. At least seven APOBEC3 proteins are present in humans, and some family members, such as APOBEC3DE (7) and APOBEC3H (21) , have only One of these proteins was similar to huAPOBEC3DE, including an insertion near the N terminus that is absent from other members of the family ( Fig. 2A) . We termed this protein rhAPOBEC3DE-I. The second protein, rhAPOBEC3DE-II, lacked the N-terminal insertion but was otherwise identical to rhAPOBEC3DE-I. The third protein, named rhAPOBEC3C, was highly homologous to huAPOBEC3C (Fig. 2B ). The rhesus macaque genome sequence contains a sequence coding for a predicted APOBEC-like 3D protein (XM_001094328); however, using primers based on this coding sequence, we were unable to amplify any APOBEC coding sequences from the 221 cell cDNA. Additionally we were unable to amplify any APOBEC3-related products using primers based on huAPOBEC3A. Using primers based on huAPOBEC3B sequences, we isolated rhAPOBEC3B (Fig. 2C) . Finally, using a mixture of primers based on human and rhesus macaque APOBEC3H, we isolated two variants of African green monkey APOBEC3H (agmAPOBEC3H) (Fig. 2D) . Each of these cDNAs, together with rhAPOBEC3G, 3F (35) , and 3H (21), was cloned into an expression plasmid introducing an N-terminal myc tag, as were human and agmAPOBEC3G, which served as controls. We next determined the ability of each APOBEC3 protein to be incorporated into HIV-1 particles. Importantly, APOBEC3 protein expression did not have any gross effects on HIV-1 GagPol expression or particle release (Fig. 3A) . All APOBEC3G proteins were well-expressed and incorporated efficiently into HIV-1 particles, as was rhAPOBEC3F (Fig. 3B ), in agreement with previous reports (1, 4, 5, 9, 10, 14, 16, 18, 24, 31, 36) . The myc-green fluorescent protein (GFP) protein used as a control for the specificity of protein incorporation into particles was not detected in the virions, even though it was expressed at levels similar to those of the APOBEC3G proteins (Fig. 3B) . Both rhAPOBEC3H and agmAPOBEC3H proteins were incorporated into particles significantly less efficiently than their APOBEC3G counterparts. Neither rhAPOBEC3B nor rhAPOBEC3B3C was incorporated into particles at detectable levels, despite being expressed at levels equivalent to that of rhAPOBEC3G. Finally, both rhAPOBEC3DE proteins were incorporated into particles at levels comparable to that of rhAPOBEC3G (Fig. 3B) .
To determine the effect of the various rhAPOBEC3 proteins on HIV-1 infectivity, increasing amounts of the APOBEC3 proteins were coexpressed with HIV-1 GagPol, a packageable HIV-1 vector expressing GFP (CSGW) and vesicular stomatitis virus G glycoprotein (VSV-G) (11) . Simultaneously, HIV-1, HIV(SEMQ) mutant, HIV-2, SIV MAC , and SIV AGM Vif proteins were expressed in trans to determine their ability to counteract APOBEC3-mediated restriction as well as their effects on APOBEC3 protein levels. All Vif proteins were expressed at similar levels (data not shown). As expected, we reproduced previously published findings on the inhibition and degradation of APOBEC3G from different species by the various Vif proteins (3, 14, 15, 17-20, 25, 28, 34, 35) . For example, all Vif proteins tested, with the exception of SIV AGM Vif, were able to decrease huAPOBEC3G expression levels and overcome huAPOBEC3G-mediated restriction (Fig. 4) . In contrast, HIV-1 Vif, unlike the other Vif proteins tested, was not able to counteract rhAPOBEC3G and agmAPOBEC3G. rhAPOBEC3F was also a very strong inhibitor of HIV-1 infectivity and was largely resistant to the Vif proteins tested (Fig.  4) (35) . The inability of SIV MAC Vif to downregulate rhAPOBEC3F efficiently is interesting, given that SIV MAC and simian-tropic HIV are capable of replicating very efficiently in rhesus macaque T cells, and suggests that the natural expression levels of rhAPOBEC3F in T cells might not be sufficiently high to inhibit virus replication.
In agreement with a previous study (21) , rhAPOBEC3H was also a very potent inhibitor of HIV-1 infectivity, decreasing titers by 100-fold (Fig. 4) . HIV-2, SIV MAC , and SIV AGM Vif profoundly reduced rhAPOBEC3H levels and overcame rhAPOBEC3H-mediated inhibition; however, both HIV-1 and the HIV(SEMQ) Vif mutant were inactive against rhAPOBEC3H. huAPOBEC3H is poorly expressed (21) (data not shown) and is therefore not a potent antiviral factor. To determine 293T cells (in 6-well plates) transfected with various myc-tagged APOBEC3 expression plasmids (900 ng per well) or a control myc-GFP expression plasmid together with an HIV-1 GagPol (450 ng per well) and a packageable genome (CSGW; 450 ng per well) were harvested 2 days posttransfection. Virions were purified by ultracentrifugation through a 20% sucrose cushion. Cell and virion lysates were analyzed by immunoblotting with an antibody against the HIV-1 capsid (A) or an antibody against the myc epitope (B). huA3G, huAPOBEC3G; agmA3G, agmAPOBEC3G; rhA3G, rhAPOBEC3G; rhA3F, rhAPOBEC3F; rhA3H, rhAPOBEC3H; rhA3B, rhAPOBEC3B; rhA3C, rhAPOBEC3C; rhA3DE-I, rhAPOBECDE-I; rhA3DE-II, rhAPOBECDE-II; agmA3H, agmAPOBEC3H. (Fig. 4 and data not shown). Specifically, agmAPOBEC3H was capable of inhibiting HIV-1 infectivity only modestly (twofold), even though it was expressed and incorporated into particles at a level similar to that of rhAPOBEC3H (Fig. 3B) . Only SIV AGM Vif was capable of completely abolishing agmAPOBEC3H inhibition and reducing its expression, while HIV-1, HIV(SEMQ), and SIV MAC Vif proteins had only marginal effects on both agmAPOBEC3H expression levels and HIV-1 infectivity (Fig. 4) . rhAPOBEC3B was also capable of reducing HIV-1 infectivity by about 10-fold and was resistant to HIV-1, HIV(SEMQ), and HIV-2 Vif proteins (Fig. 4) . In contrast, both SIV MAC and SIV AGM Vif proteins efficiently downregulated rhAPOBEC3B protein levels and rescued HIV-1 infectivity. The ability of rhAPOBEC3B to inhibit HIV-1 infectivity was surprising, given that undetectable levels were incorporated into HIV-1 particles (Fig. 3B) . rhAPOBEC3DE-II, but not rhAPOBEC3DE-I, showed some antiviral activity against HIV-1, reducing titers by about sevenfold (Fig. 4A) . Restriction was overcome by SIV MAC , SIV AGM , and, surprisingly, HIV-1 Vif but not HIV-2 or HIV(SEMQ) Vif proteins (Fig. 4) . In contrast, rhAPOBEC3C did not significantly inhibit HIV-1 (Fig. 4A) . Interestingly, HIV-2, SIV MAC , and SIV AGM Vif dramatically reduced rhAPOBEC3C expression (Fig. 4B) . This activity could be biologically relevant, because huAPOBEC3C inhibits SIV MAC but not HIV-1 (33) , and it is possible that the same is true of rhAPOBEC3C.
This study demonstrates that several members of the APOBEC3 family can potentially inhibit HIV-1 replication in rhesus macaque cells (Table 1 ). In addition to confirming that the well-characterized rhAPOBEC3G and rhAPOBEC3F can inhibit HIV-1 infectivity, we confirmed the results of a previous study (21) that demonstrated that rhAPOBEC3H can also inhibit HIV-1 infectivity. rhAPOBEC3H is incorporated into HIV-1 particles significantly less efficiently than rhAPOBEC3G, yet, surprisingly, can inhibit HIV-1 infectivity more potently. This is not a general property of Old World monkey APOBEC3H proteins and was not conserved in agmAPOBEC3H. Importantly, rhAPOBEC3H-mediated inhibition cannot be overcome by a mutant HIV-1(SEMQ) Vif protein that can target rhAPOBEC3G. Recently, it was reported that the determinants of interaction with huAPOBEC3G and huAPOBEC3F map to different regions of the HIV-1 Vif protein (22, 29, 32) . Evidently, the determinants of rhAPOBEC3H recognition are also different from those of rhAPOBEC3G. This also applies to rhAPOBEC3B. huAPOBEC3B may inhibit HIV-1 and cannot be counteracted by HIV-1 or SIV MAC Vif (8, 33) ; however, rhAPOBEC3B is sensitive to SIV MAC but not HIV-1 or HIV(SEMQ) Vif. Furthermore, rhAPOBEC3B may be unusually potent or inhibit HIV-1 infectivity by a mechanism different from that of other APOBEC3 proteins, as it was undetectable in HIV-1 particles. Interestingly, the modest inhibition of infectivity mediated by rhAPOBEC3DE-II could be overcome by HIV-1 but not HIV(SEMQ) Vif, suggesting that rhAPOBEC3DE is recognized by overlapping Vif determinants, as is rhAPOBEC3G, but imposes different amino acid requirements for interaction on Vif. Overall, we found a very good correlation between the ability of each Vif protein to reduce the various APOBEC3 protein levels and its ability to rescue HIV-1 infectivity. Of the Vif proteins tested herein, HIV-1 Vif appeared to have the most-limited breadth of activity against rhAPOBEC3 and agmAPOBEC3 proteins, whereas SIV MAC and SIV AGM Vif proteins had significantly broader specificities. Moreover, HIV-2 Vif did not inhibit as wide a range of APOBEC3 proteins as SIV MAC Vif, even though these viruses are closely related. In conclusion, this study suggests that a number of APOBEC3 proteins could limit crossspecies lentivirus transmission and that future attempts to engineer HIV-1 Vif so as to allow the virus to replicate in rhesus macaque T cells will have to take into account the activity of several rhAPOBEC3 proteins.
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a ϩϩϩ, Ͼ10-fold inhibition of HIV-1 infectivity; ϩϩ, ϳ10-fold inhibition of HIV-1 infectivity; ϩ, Ͻ10-fold inhibition of HIV-1 infectivity; Ϫ, twofold or lower inhibition of HIV-1 infectivity.
b None indicates no Vif protein.
